Top Markets
#1 Black Phoenix Black Phoenix +826.64%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.17%
#3 Beam Beam +24.88%
#4 Bless Bless +21.52%
#5 Tutorial Tutorial +21.07%
#6 SAFEcoin SAFEcoin +20.45%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +19.37%
#8 Magma Finance Magma Finance +17.16%
#9 THORChain THORChain +17.07%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +15.57%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Alamar Biosciences, Inc. Alamar Biosciences, Inc.

Alamar Biosciences, Inc.

ALMR
Rank in Stocks #5889
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing... Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Share Price
$34.56
Market Cap
$2.40B
Change (1 day)
1.41%
Change (1 year)
-
Country
US
Trade Alamar Biosciences, Inc. (ALMR)

Category

Healthcare
Revenue for Alamar Biosciences, Inc. (ALMR)
Revenue in Aug 2026 TTM: 0
According to Alamar Biosciences, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Alamar Biosciences, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH